GlassScriptPhysician profile
Asim Razzaq
NPI 1790758514
$8,571.24
in general payments reported to CMS, 2019-2025
30 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,281 · 2020: $1,576 · 2021: $1,269 · 2022: $1,126 · 2023: $732 · 2024: $502 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.49 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,914.08 | 2019-2025 | |
| Amgen INC. | $1,390.54 | 2019-2025 | Krystexxa, Evenity, Enbrel |
| Novartis Pharmaceuticals Corporation | $911.81 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $563.44 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $549.41 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $522.88 | 2019-2023 | Taltz |
| Pfizer INC. | $425.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $394.14 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $376.82 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $232.78 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $231.22 | 2019-2021 | |
| Genzyme Corporation | $153.62 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $144.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $142.33 | 2021-2024 | Saphnelo |
| Hikma Pharmaceuticals USA | $127.17 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $88.68 | 2020-2022 | |
| Celgene Corporation | $80.51 | 2019 | |
| Radius Health, INC. | $65.68 | 2019-2021 | |
| Sobi, INC | $42.81 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $28.96 | 2019 | |
| Medexus Pharma, INC. | $26.03 | 2019 | |
| Merck Sharp & Dohme LLC | $24.80 | 2019 | |
| Ani Pharmaceuticals, INC. | $22.84 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.76 | 2025 | Adstiladrin |
| Aurinia Pharma U.S., INC. | $18.33 | 2025 | Lupkynis |
| Pacira Therapeutics, INC. | $18.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.32 | 2021 | |
| Sumitomo Pharma America, INC. | $14.67 | 2024 | Orgovyx |
| Hologic Sales and Service, LLC | $13.33 | 2021 | |
| Daiichi Sankyo INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Razzaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.